Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJAY | ISIN: US19240Q2012 | Ticker-Symbol:
NASDAQ
23.04.25
21:59 Uhr
4,465 US-Dollar
0,000
0,00 %
1-Jahres-Chart
COGENT BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
COGENT BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur COGENT BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
25.03.Cogent Biosciences, Inc.: Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting2
25.02.Cogent Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
25.02.Cogent Biosciences, Inc. - 10-K, Annual Report-
COGENT BIOSCIENCES Aktie jetzt für 0€ handeln
25.02.Cogent Biosciences, Inc. - 8-K, Current Report-
10.02.Cogent Biosciences, Inc.: Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting2
16.01.Hedge Fund and Insider Trading News: Bill Ackman, Scott Bessent, Alden Global Capital, Saba Capital, Point72 Asset Management, Citadel Investment Group, Cogent Biosciences Inc (COGT), Immunovant Inc (IMVT), and More4
13.01.Cogent Biosciences sets key 2025 milestones for drug trials1
13.01.Cogent Biosciences legt wichtige Meilensteine für Medikamentenstudien bis 2025 fest2
09.12.24Cogent Biosciences, Inc. - 8-K, Current Report-
09.12.24Why Is Cogent Biosciences Stock Trading Higher On Monday?1
09.12.24Cogent Biosciences, Inc.: Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients25356% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS 89% of patients had >50% decrease in serum tryptase by...
► Artikel lesen
08.12.24Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)15552% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with...
► Artikel lesen
12.11.24Cogent Biosciences GAAP EPS of -$0.64 misses by $0.081
06.08.24Cogent Biosciences, Inc.: Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results351SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025 Ended 2Q 2024 with $390 million, sufficient to fund...
► Artikel lesen
14.06.24Cogent Biosciences, Inc.: Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)246Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions Reductions were shown in all individual MS2D2 symptoms across domains...
► Artikel lesen
23.05.24Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting245Bezuclastinib + sunitinib combination therapy reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior treatment Encouraging long-term...
► Artikel lesen
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1